知镜 Cognispect · 医学文献与研究工作台

Adjunctive transcranial DC stimulation in the management of refractory drug-resistant focal epilepsy in POLG mitochondrial disease: A case series.

Bangel KA, Ng Y, Lim A, Thomas NJP, Jaiser SR, Lai HM, Gorman GS, Thomas RR, Turnbull DM, Ramesh V, Schaefer AM, McFarland R, Baker MR.
Seizure · 2026-05-09 · PMID 42248710

文献摘要

Background Pathogenic POLG variants produce an age-related progressive multi-system mitochondrial disorder, with neurologic manifestations that include focal onset seizures, stroke-like episodes, cerebellar ataxia, sensory neuronopathy, complex ophthalmoplegia and myopathy. Focal onset status epilepticus or epilepsia partialis continua (EPC) frequently occurs in patients with paediatric and early adulthood onset disease. Methods Between 2014 and 2020, we treated 15 episodes of drug-refractory focal epileptic status (epilepsia partialis continua) in 5 patients with POLG-related mitochondrial disease with cathodal transcranial direct current stimulation (tDCS). Here we describe the management of each episode of EPC, including the application of tDCS. Results Transcranial DCS, delivered for 20 min at 2 mA, once daily (minimum 3 days; maximum 14 days), as an adjunct to optimal standard medical care, was associated with a significant reduction (93% of episodes after 4.3 sessions) or a cessation of seizures (63% of episodes after 8.4 sessions). No major side effects of tDCS were noted. Conclusion Our findings support further exploration of tDCS as a potential adjunctive therapy for complex neurological challenges in mitochondrial disorders.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。